Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1CNS 1

Conditions

Neoplasms 2Solid Tumours 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Lymphoma 1Carcinoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 32Filgrastim 18Irinotecan 15Topotecan 14Temozolomide 13Vincristine 12Peripheral Blood Stem Cell Transplantation 12Granulocyte Colony-Stimulating Factor 12Etoposide 12Melphalan 11fludarabine 10Carboplatin 9dinutuximab 8Isotretinoin 8Interleukin-2 8Busulfan 8humanized 3F8 anti-GD2 monoclonal antibody 7aldesleukin 7Doxorubicin 73-Iodobenzylguanidine 7sargramostim 6fludarabine phosphate 6Vorinostat 6Zoledronic Acid 5Stem Cell Transplantation 5Cisplatin 5etoposide phosphate 4Ipilimumab 4Drug Therapy 4ribociclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroblastoma × molibresib × Clear all
NCT01587703 2020-03-16

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

GlaxoSmithKline

Phase 1 Completed
196 enrolled 78 charts
CNSPlasma cellThoracic

Carcinoma, Multiple Myeloma, Neoplasms, Neuroblastoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡